Successful treatment of a 2-year-old girl with intractable myasthenia gravis using tacrolimus

Brain and Development

Volumn 28, Issue 8, 2006, Pages 534-536

  Kakisaka, Yosuke ^a   Haginoya, Kazuhiro ^a   Yokoyama, Hiroyuki ^a   Ishitobi, Mamiko ^a   Wakusawa, Keisuke ^a   Sato, Ikuko ^a   Togashi, Noriko ^a   Kitamura, Taro ^a   Fukuyo, Naomi ^a   Yoshihara, Yasushi ^b   Iinuma, Kazuie ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Childhood; Immunosuppressant; Myasthenia gravis; Tacrolimus

Indexed keywords

IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; PYRIDOSTIGMINE; TACROLIMUS;

ANAMNESIS; ARTICLE; CASE REPORT; CHILDHOOD DISEASE; CLINICAL EXAMINATION; DRUG EFFICACY; FEMALE; HUMAN; MYASTHENIA GRAVIS; OROPHARYNX; PHYSICAL EXAMINATION; PRESCHOOL CHILD; REMISSION; TREATMENT OUTCOME;

CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745912232     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2006.02.001     Document Type: Article

References (10)

1. Wolfe G.I., and Barohn R.J. Neuromuscular junction disorder of childhood. In: Swaiman K.F., and Ashwal F. (Eds). Pediatric neurology. 3rd ed. (1999), Mosby, St. Louis 1216-1226
2. Yoshikawa H., Mabuchi K., Yasukawa Y., Takamori M., and Yamada M. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 9 (2002) 627-628
3. Konishi T., Yoshiyama Y., Takamori M., Yagi K., Mukai E., Saida T., et al. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 28 (2003) 570-574
4. Evoli A., Schino C.D., Marsili F., and Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 25 (2002) 111-114
5. Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. 1. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 40 (1987) 1249-1255
6. Tocci M.J., Matkovich D.A., Collier K.A., Kwok P., Dumont F., Lin S., et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143 (1989) 718-726
7. Laskow D.A., Vincenti F., Neylan J., Mendez R., and Matas A.J. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 62 (1996) 900-905
8. Shibata M., Suzuki Y., Takenaka M., Yamada T., Hattori T., Kinpara Y., et al. A case of intractable childhood-onset systemic myasthenia gravis that was successfully treated with tacrolimus. Shounika Rinsho (in Japanese) 56 (2003) 1939-1942
9. Takamori M., Motomura M., Kawaguchi N., Nemoto Y., Hattori T., Yoshikawa H., et al. Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 62 (2004) 1894-1896
10. Davies T.H., Ning Y.M., and Sanchez E.R. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 44 (2005) 2030-2038